Floatz logo

Cyclophosphamide

Radiotherapy; Complications

RenJi HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Radiotherapy; Complications cohort.

Asset / SponsorPhaseRating
RAMIPRIL
Wake Forest University Health Sciences
Phase 2B
Tislelizumab
RenJi Hospital
N/AD
LENVATINIB
RenJi Hospital
N/AD
Epirubicin
RenJi Hospital
N/AD
Pyrotinib
RenJi Hospital
N/AD
rc48-adc
RenJi Hospital
N/AD
Pembrolizumab
RenJi Hospital
N/AD

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →